Condition

Non-squamous Non-small Cell Lung Cancer clinical trials and research

• 12Clinical trials
• 1New in 30 days
• 28Countries

Newest Non-squamous Non-small Cell Lung Cancer clinical trials

All recruiting trials (12)

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Aglatimagene Besadenovec with Prodrug and Pembrolizumab vs Docetaxel for Advanced Non-Squamous NSCLC

  This phase 3 trial tests whether giving aglatimagene besadenovec with a prodrug and pembrolizumab works better than standard chemotherapy (docetaxel) for adults with stage IV non-squamous NSCLC that progressed on pembrolizumab.

  Recruiting Phase 3 Candel Therapeutics, Inc. · New York, New York · NCT07660094

• IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)

  A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.

  Recruiting at 6 sites Phase 1/2 InduPro, Inc. · Los Angeles, California and 5 other locations · NCT07602842

• BL-M07D1 plus pembrolizumab for advanced HER2‑overexpressing non-squamous NSCLC

  This treatment combines BL-M07D1 with pembrolizumab to see if it helps people with unresectable locally advanced or metastatic HER2‑overexpressing non‑squamous non‑small cell lung cancer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07264816

• BL-M07D1 versus pembrolizumab-plus-platinum chemo for first-line HER2‑mutant advanced non-squamous lung cancer

  This trial will test whether BL-M07D1 works better than pembrolizumab combined with platinum chemotherapy as the first treatment for people with HER2‑mutant advanced or metastatic non-squamous non-small cell lung cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07178795

• Telisotuzumab adizutecan plus osimertinib for first-line treatment of advanced EGFR-mutated non-squamous NSCLC

  This test adds the investigational drug telisotuzumab adizutecan to osimertinib (or to osimertinib plus chemotherapy) to see if it helps adults with newly diagnosed advanced EGFR-mutated non-squamous non-small cell lung cancer and to check side effects.

  Recruiting at 63 sites Phase 2/3 AbbVie · Chandler, Arizona and 64 other locations · NCT07005102

• JS207 (PD‑1/VEGF bispecific) plus chemotherapy for advanced non-squamous NSCLC after TKI failure

  This trial will test whether combining JS207 with pemetrexed and platinum chemotherapy can help people with advanced non-squamous NSCLC who have driver gene changes and have stopped responding to TKIs.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Guangzhou, Guangdong · NCT06868836

• Comparing Rilvegostomig and Pembrolizumab with Chemotherapy for Lung Cancer

  This study is testing whether a new drug called rilvegostomig or pembrolizumab, both used with chemotherapy, can help people with advanced lung cancer whose tumors have a specific marker.

  Recruiting at 246 sites Phase 3 AstraZeneca · Mobile, Alabama and 300 other locations · NCT06627647

• Assessment of outcomes in non-squamous lung cancer patients after chemotherapy failure in Brazil

  This study looks at how well different treatments work for patients in Brazil with advanced non-squamous lung cancer who didn't respond to their initial chemotherapy.

  Recruiting at 5 sites AstraZeneca · Belo Horizonte, Minas Gerais and 10 other locations · NCT06491862

• HS-20117 combined with aumolertinib for advanced EGFR‑mutant non-squamous lung cancer

  This tests whether adding the bispecific antibody HS-20117 to aumolertinib helps people with advanced, treatment‑naive, EGFR‑mutant non‑squamous non‑small cell lung cancer live longer or have better tumor control.

  Recruiting at 2 sites Phase 2/3 Hansoh BioMedical R&D Company · Tianjin, Tianjin Municipality and 1 other locations · NCT06417008

• Combining Camrelizumab with Pemetrexed and Carboplatin for Lung Cancer Treatment

  This study is testing if a new combination of camrelizumab with two other drugs can help people in Korea with advanced lung cancer feel better and improve their treatment outcomes.

  Recruiting at 8 sites Phase 2 CrystalGenomics, Inc. · Anam and 7 other locations · NCT05841472

Related topics

Quick answers

How many Non-squamous Non-small Cell Lung Cancer clinical trials are recruiting right now?

12, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 28 countries. The most sites are in China (6 trials), United States (6 trials), South Korea (3 trials), Australia (2 trials), Belgium (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 4, Phase 2: 3, Phase 2/3: 2, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →